Literature DB >> 7768785

Biochemical comparison of imipenem, meropenem and biapenem: permeability, binding to penicillin-binding proteins, and stability to hydrolysis by beta-lactamases.

Y Yang1, N Bhachech, K Bush.   

Abstract

Biological activities of biapenem, imipenem, and meropenem were compared with respect to permeability into Gram-negative bacteria, binding to penicillin-binding proteins (PBPs), and hydrolysis by beta-lactamases. Permeability for the three carbapenems was similar when measured in Serratia marcescens S6 producing a carbapenem-hydrolyzing beta-lactamase. Penetration of the carbapenems was comparable with cephaloridine and faster than piperacillin or the extended spectrum cephalosporin cefotaxime. All the carbapenems bound most strongly to PBP 2 of Escherichia coli and Pseudomonas aeruginosa, and to PBP 1 of Staphylococcus aureus. In addition, biapenem showed strong affinity with PBP 1a of E. coli and PBP 1b of P. aeruginosa. Selected serine beta-lactamases, including the extended spectrum plasmid-mediated beta-lactamases, hydrolyzed these carbapenems at rates < 0.1% that of cephaloridine. Metallo-beta-lactamases hydrolysed the carbapenems at measurable rates, with enzymes from Bacteroides fragilis and Xanthomonas maltophilia hydrolyzing biapenem at lower Vmax values than meropenem or imipenem. In conclusion, all the carbapenems exhibited good rates of penetration, bound strongly to PBPs in both Gram-negative and Gram-positive bacteria, and were stable to most Group 1 and Group 2 serine beta-lactamases, but were hydrolyzed by metallo-beta-lactamases.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7768785     DOI: 10.1093/jac/35.1.75

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  47 in total

1.  In vitro activities of the potent, broad-spectrum carbapenem MK-0826 (L-749,345) against broad-spectrum beta-lactamase-and extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli clinical isolates.

Authors:  J Kohler; K L Dorso; K Young; G G Hammond; H Rosen; H Kropp; L L Silver
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

Review 2.  Comparative pharmacokinetics of the carbapenems: clinical implications.

Authors:  J W Mouton; D J Touzw; A M Horrevorts; A A Vinks
Journal:  Clin Pharmacokinet       Date:  2000-09       Impact factor: 6.447

3.  Evaluation of imipenem for prophylaxis and therapy of Yersinia pestis delivered by aerosol in a mouse model of pneumonic plague.

Authors:  Henry S Heine; Arnold Louie; Jeffrey J Adamovicz; Kei Amemiya; Randy L Fast; Lynda Miller; Steven M Opal; John Palardy; Nicolas A Parejo; Fritz Sörgel; Martina Kinzig-Schippers; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

4.  AmpC and OprD are not involved in the mechanism of imipenem hypersusceptibility among Pseudomonas aeruginosa isolates overexpressing the mexCD-oprJ efflux pump.

Authors:  Daniel J Wolter; Nancy D Hanson; Philip D Lister
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

Review 5.  Investigational antimicrobial agents of 2013.

Authors:  Michael J Pucci; Karen Bush
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

Review 6.  The Role of Antibiotics in Modulating Virulence in Staphylococcus aureus.

Authors:  Elisabeth Hodille; Warren Rose; Binh An Diep; Sylvain Goutelle; Gerard Lina; Oana Dumitrescu
Journal:  Clin Microbiol Rev       Date:  2017-10       Impact factor: 26.132

7.  Evidence for a peptidoglycan-like structure in Orientia tsutsugamushi.

Authors:  Sharanjeet Atwal; Suparat Giengkam; Suwittra Chaemchuen; Jack Dorling; Nont Kosaisawe; Michael VanNieuwenhze; Somponnat Sampattavanich; Peter Schumann; Jeanne Salje
Journal:  Mol Microbiol       Date:  2017-06-19       Impact factor: 3.501

8.  Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.

Authors:  Todd A Davies; Malcolm G P Page; Wenchi Shang; Ted Andrew; Malgosia Kania; Karen Bush
Journal:  Antimicrob Agents Chemother       Date:  2007-04-30       Impact factor: 5.191

Review 9.  Newer antibacterial drugs for a new century.

Authors:  Gina Devasahayam; William M Scheld; Paul S Hoffman
Journal:  Expert Opin Investig Drugs       Date:  2010-02       Impact factor: 6.206

10.  In vitro activity of Biapenem plus RPX7009, a carbapenem combined with a serine β-lactamase inhibitor, against anaerobic bacteria.

Authors:  Ellie J C Goldstein; Diane M Citron; Kerin L Tyrrell; C Vreni Merriam
Journal:  Antimicrob Agents Chemother       Date:  2013-03-25       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.